INVESTOR PRESENTATION SEPTEMBER 2017

Similar documents
One of the oldest and largest FMCG Companies in the country. World s largest in Ayurveda and natural healthcare

Dabur India Ltd. Investor Presentation June 2016

Dabur India Limited. Investor Communication. Quarter and Nine months ended 31 st December, 2016

Investor Presentation. February 2018

Investor Presentation. November 2017

Investor Presentation. February 2018

Dabur India Limited. Quarter ended 31 st December Investor Presentation. 31 January

Dabur India Limited. October 10, CMP (Rs.) 284. Key Developments

Sub: Submission of information under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dabur India Ltd. BUY CMP (Rs.) 277 Target (Rs.) 344 Potential Upside 24% Investment Rationale. Volume No.. I Issue No. 40. September 8 th, 2015

DABUR INDIA LTD. Stock Coverage BUY CMP TARGET 515 LONG TERM INVESTMENT. Date 02 nd Aug BSE Code

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-JUNE 2014

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Q Investor Kit JANUARY-MARCH 2013

Summary of Results for the First Half of FY2015/3

Q Investor Kit JANUARY-JUNE 2013

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

BUY. Dabur India Ltd. FMCG RETAIL EQUITY RESEARCH. Set to ride the herbal wave. GEOJIT BNP PARIBAS Research

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

DELICA D:5 ACTIVE GEAR 0

For personal use only

Consumer Wellness in India Growth Ahead

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Third-quarter results 2013

Q Investor Kit January December 2014

1Q 2014 Earnings Release

Q2 INVESTOR KIT JANUARY-JUNE 2011

BALCHEM CORPORATION. Q Investor Relations Presentation

M e d i a s e t G r o u p

ABOUT. CIEL Healthcare Limited ( CHL ), a subsidiary of CIEL Limited, is a Mauritian registered private limited

THIRD QUARTER REPORT 2011 (UNAUDITED)

Insert Cover Image using Slide Master View Do not distort. Anti-Diabetic Pharmaceuticals Market - India

Woongjin Coway. 1Q 12 IR Presentation

For personal use only

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Endesa 1Q 2017 Results 09/05/2017

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Forward Looking Information

Consolidated: Financial Summary

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

Shareholder Presentation Annual Meeting 2018

Welcome to LG Electronics

SUMMARY TERM SHEET. Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL )

May 6, 2008 First Quarter 2008 Results

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

INDO-AFRICA PHARMA BUSINESS MEET

Financial Presentation

Investor Relations 1Q 2017

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Colgate Palmolive India Limited Slide 1

Essential Oil & Aromatherapy Market Research Report- Forecast to 2023

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

The World Bank: Policies and Investments for Reproductive Health

Key figures (consolidated)

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

Interim report Second quarter 2017 and subsequent events (Unaudited)

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

Slide 1. Investor presentation. London 5 February 2019

Business Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )

Investor Presentation. Q April 26, 2018

Südzucker Group Capital market forum Rhine Neckar

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

1Q 2015 Results A Positive Start to 2015

Investor Presentation. Q October 26, 2017

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

Presentation of. Burgdorf, 1 st November 2012

A world leader in allergy immunotherapy

FY 2014 Results Presentation. 24 February, 2015

2010 First Quarter Results Presentation. 11 th May 2010

Total Face Group Limited

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

Cochlear Limited 2017 Annual General Meeting Chairman s Address

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Coloplast A/S. Investor presentation 1H 2005/06

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Global Market Analysis of Herbal Drug Formulations Joshi Nirali B 1 * and M. B. Shankar 2

Value growth in Human Nutrition & Health

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty

ASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012

Leading Intimate Healthcare. Investor presentation Q1 2007/08

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

Summary Statement of Financial Position (consolidated)

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

Q Investor Kit January December 2015

APPLIANCE TELECOMMUNICATIONS

Consumer Care A Strong Foundation in Consumer Health

Karel Stoschek Director Infant Nutrition. Infant Nutrition

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

The Cigarette Market in Saudi Arabia

Transcription:

INVESTOR PRESENTATION SEPTEMBER 2017

DABUR OVERVIEW One of the oldest and largest FMCG Companies in the country World s largest in Ayurveda and natural healthcare Total reach of 6 mn outlets, one of the highest among FMCG companies Nineteen world class manufacturing facilities catering to needs of diverse markets Strong overseas presence with 30% contribution to consolidated sales 1.

STRONG FINANCIAL PROFILE Sales In INR Bn Profit After Tax (PAT) 61.5 70.7 78.1 78.5 76.8 13.0 11.0 9.0 7.0 PAT PAT margin (%) 12.5 12.8 10.7 9.1 16.6% 15.9% 7.6 13.7% 12.4% 12.9% 18.0% 16.0% 14.0% 12.0% 10.0% 5.0 8.0% 3.0 6.0% 4.0% 1.0 2.0% FY13 FY14 FY15 FY16 FY17-1.0 FY13 FY14 FY15 FY16 FY17 0.0% Operating Profit Operating Profit Operating margin (%) 20.0 25.0% 18.0 16.0 14.0 12.0 10.0 13.2 11.6 10.0 16.3% 16.3% 16.9% 15.1 15.2 19.2% 19.8% 20.0% 15.0% 8.0 10.0% 6.0 4.0 5.0% 2.0 0.0 FY13 FY14 FY15 FY16 FY17 0.0% FY16 and FY17 are basis IND AS 2.

STRONG FINANCIAL PROFILE Shareholders' Funds ROIC In INR Bn 33.5 41.7 48.5 38.3% 43.6% 45.2% 53.0% 47.9% 21.0 26.6 FY13 FY14 FY15 FY16 FY17 FY13 FY14 FY15 FY16 FY17 Earnings Per Share In INR 6.1 7.1 7.2 5.2 4.4 FY13 FY14 FY15 FY16 FY17 FY16 and FY17 are basis IND AS 3.

MANUFACTURING FACILITIES Twelve Domestic Manufacturing Locations in India Baddi, Himachal Pradesh Pantnagar, Uttaranchal Sahibabad, Uttar Pradesh Jammu, J&K Silvasa,Dadra & NagarHaveli Alwar, Rajasthan Katni, Madhya Pradesh Narendrapur,West Bengal Pithampur, Madhya Pradesh Tezpur, Assam Newai, Rajasthan Nasik, Maharashtra Seven International Manufacturing Locations UAE Egypt Nigeria Turkey Sri Lanka Bangla desh Nepal 4.

TEZPUR PLANT New manufacturing facility commissioned in Tezpur, Assam in March 17. Investment of Rs 250 Crore Largest production facility for Dabur across the globe Will manufacture entire range of Dabur's Ayurvedic Medicines, Health Supplements, Hair Oils, Shampoos, Toothpastes, Skin Care and Home Care products Spread over 30 acres of land, this factory features fully automated processing lines and automated packing lines to optimize supply chain and quality management with special focus on environment and sustainability 5.

DISTRIBUTION NETWORK URBAN RURAL Factory Factory C&F C&F GT Stockist MT Stockist Insti Stockist Super Sockist Wholesaler Sub Sockist Retailer Retailer Retailer Consumer Consumer Consumer Consumer Distribution reach of 6 mn retail outlets; Cover over 45000 villages directly 6.

DISTRIBUTION INITIATIVES Focus on enhancing field efficiencies Inducted around 1000 Village salesmen on company rolls Increase the outlet coverage per SSM Increasing Direct Reach Near term target to increase direct reach to 1 mn outlets Product Focus Rural Focused Product Mix Innovative launches in Urban Capability enhancement through training and IT enablement Focus on alternative channels- Increased role of Modern Trade, Cash & Carry and E Commerce 7.

WHAT IS AYURVEDA? Ayurveda is the traditional system of healthcare which promotes PREVENTION and CURE Ayurveda is based upon Natural Remedies which incorporate the healing properties of plants and herbs. It is a holistic system which heals by activating the natural inherent curative force of the body 8.

DABUR & AYURVEDA Dabur has created the Ayurveda eco system over many decades involving R&D, medical fraternity, hospitals, patients along with manufacturing and selling the entire product range of Classical Ayurveda 9.

CLAIM BASED COMMUNICATION Double immunity 2X faster physical growth Clinically proven formula Clinically proven formula Stay fit, feel young Dabur focuses on evidence based claims for its products 10.

PROMOTING AYURVEDA: DOCTOR REACH Directly reaching 32000+ Doctors Detailing and Product sampling Connecting Engaging Collaborating Promoting Association with 50 + Ayurvedic Colleges www.dabur mediclub.com Key Opnion Leaders 11.

DABUR BUSINESS STRUCTURE Dabur India Ltd. Domestic (70%) International (30%) Domestic FMCG (66%) Others (4%) Organic (69%) Acquired (31%) * Others include Retail, Commodity exports etc Note: % figure in brackets indicate % share in Consolidated Sales for FY17 12.

INDIA BUSINESS 13.

SALES BY BUSINESS VERTICAL Domestic FMCG* Healthcare (31%) HPC (50%) Foods (19%) Domestic FMCG* Business Breakdown * Breakdown of Domestic FMCG business basis FY17 Sales Skin & Salon 5% Home Care 7% Foods 19% Oral Care 16% Health Supplements 17% Hair Care 22% Digestives 5% OTC& Ethicals 9% 14.

MARKET LEADER IN 6 CATEGORIES Leading position in key categories across verticals #Relative Competitive Position #1 #1 #2 #2 #2 #1 #1 #2 #3 #1 #1 Healthcare Home and Personal Care Foods * Position basis Nielsen Market Share data MAT Mar 17 15.

BUSINESS STRATEGY Healthcare Leadership in Ayurveda scientific evidence & research OTC portfolio to be scaled up through innovation & awareness creation Doctor advocacy through Medico Marketing channel Home & Personal Care Ayurvedic / Herbal focus Premiumization & Differentiation Strong innovation agenda Foods Maintain leadership in Juices & Nectars category Leveraging the Fruit equity associated with the Real brand Focus on Healthy range of products 16.

FOCUS ON INNOVATIONS 17.

CONTINUE TO BUILD BIGGER BRANDS 16 brands with turnover of INR 1bn+ with 3 brands over 10bn 18.

MOST TRUSTED BRANDS Dabur Red Paste and Dabur Hajmola have been ranked amongst the biggest gainers in the latest Brand Equity Most Trusted Brands List Dabur Red Paste moved up 66 places and was ranked 34 in the Brand Equity Most Trusted Brands 2016 list, released by The Economic Times, up from its ranking of 100 in the previous year In the Oral Care category list, Dabur Red Paste took the third place, a gain of one rank from the previous year. The year 2016 had seen Dabur Red Paste also break into the Top 3 in the market, becoming the third largest toothpaste brand in the country. Hajmola gained 38 places and was ranked 85 in the list. The brand was also ranked in the Top 5 in the OTC category for 2016 19.

INTERNATIONAL BUSINESS 20.

BUSINESS OVERVIEW In INR Mn 23108 24226 24520 23199 18338 FY16 and FY17 are basis IND AS FY13 FY14 FY15 FY16 FY17 Regionwise Sales:FY 2016-17 Middle East Saudi Arabia, UAE Americas 17% Europe 13% Asia 19% Middle East 31% Africa 20% Africa Europe Asia America Egypt, Nigeria, Kenya, South Africa Turkey, UK Nepal, Bangladesh, Pakistan USA 21.

THE JOURNEY 2011-2014 2015-2018 2007-10 2002 Trading Model through a franchisee Hair Oil was mainstay No localization 2003-2006 Franchisee bought out and renamed Dabur International Portfolio expansion beyond Hair Oils Focus on building demand Entry into Personal Care segments Manufacturing locations expanded Systems and processes implemented Hobi and Namaste acquired which led to geographic expansion Innovative product offerings Management bandwidth expanded Enter into African Markets Expand portfolio Cross pollinate ideas and leanings from different units 22.

ORGANIC INTERNATIONAL BUSINESS Oral Care 2% Others 5% Skincare 8% Others 5% Oral Care 12% Hair Oil 37% Hair Oil 93% Hamamzaith & Styling 12% Shampoo 14% Hair Cream 12% The Organic International Business has evolved from being just a Hair Oil business to a diversified personal care entity 23.

RECENT INNOVATIONS - IBD 24.

IBD : BUSINESS STRATEGY Capitalize on the Herbal Wave trend Focus on Core Categories like Hair Care, Oral Care and Skin Care Leveraging Digital platform to enhance consumer awareness and brand visibility Optimize Advertising spends and capture better efficiencies Continued focus on brand innovation and renovation 25.

CONSOLIDATED PERFORMANCE : FY17 In INR Mn 78507 Sales PAT 12770 76801 12511 FY16 FY17 FY16 FY17 Sales for FY17 declined by 2.2% and stood at Rs.76.8 bn. However, Sales were flattish in constant currency terms PAT increased by 2.1% and stood at Rs.12.77 bn. Operating margin increased from 19.3% in FY16 to 19.6% in FY17 Domestic business was impacted because of trade disruption and pipeline correction during demonetisation International business faced headwinds because of geo political disturbance in the Middle East and currency volatility in Egypt, Nigeria and Turkey 26.

GST IMPACT Netting of GST from sales will reduce topline by around 5% No material impact on bottomline as net effect of GST is more or less neutral GST roll off has been smooth with all direct channel partners coming on board Wholesale trade yet to come back to normalcy; however other channels such as Cash & Carry, Modern Trade, E commerce and Super-Sub networks have picked up Trade de-stocking preceding the GST implementation hurt sales in Q1FY18 However longer term GST should be positive for the sector with increasing compliance and streamlining of logistics and supply chain. 27.

SUSTAINABILITY: A KEY FOCUS 2537 farmers/beneficiaries of our Agronomical initiatives in India 9.3 lakh saplings of rare herbs distributed free of cost to farmers 1253 Household toilets constructed 2374 students benefited from School Support Programmes 393 Women gained literacy at our Adult literacy centres 510 women trained at our vocational training centers 28.

SHAREHOLDING, M CAP AND DIVIDEND 439 Market Cap 488 546 In INR Bn FIIs, 17.5% DIs, 8.9% Promoters, 68.1% Retail, 5.6% Mar'16 Mar'17 Aug'17 Dividend History 175% 150% 175% 200% 115% 130% 150% 175% 200% 225% 225% FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 29.

CONSOLIDATED P&L : FY2016-17 DIL (Consolidated) P&L FY17 FY16 YoY (%) Net Sales 76,801 78,507-2.20% Other Operating Income 214 180 18.40% Material Cost 38,432 38,496-0.20% % of Sales 50.0% 49.0% Employee Expense 7,896 7,941-0.60% % of Sales 10.3% 10.1% Advertising & Publicity 6,461 7,716-16.30% % of Sales 8.4% 9.8% Other Expenses 9,135 9,352-2.30% % of Sales 11.9% 11.9% Operating Profit 15,089 15,183-0.60% % of Sales 19.6% 19.3% Other Non Operating Income 2,983 2,172 37.40% EBITDA 18,073 17,355 4.10% % of Sales 23.5% 22.1% Finance Costs 540 485 11.40% Depreciation & Amortization 1,429 1,332 7.30% Profit Before Tax (PBT) 16,104 15,538 3.60% Tax Expenses 3,303 2,999 10.10% PAT 12,801 12,539 2.10% Minority Interest - Profit/(Loss) 34 27 Share of profit / (loss) of associates & joint venture 3-0 PAT (After Minority Int) 12,770 12,511 2.10% % of Sales 16.6% 15.9% In INR Mn Note: IND AS implemented w.e.f 1 St April, 2016 30.

STATEMENT OF ASSETS AND LIABILITIES Particulars 31.3.2017 31.3.2016 ASSETS Non-current assets (a) Property, plant and equipment 14,790 12,388 (b) Capital work-in-progress 421 448 (c) Investment property 550 606 (d) Goodwill 4,105 4,105 (e) Other Intangible assets 139 181 (f) Financial assets (i) Investments 24,994 18,809 (ii) Others 124 132 (g) Other non-current assets 1,023 498 Total Non-current assets 46,146 37,166 Current assets (a) Inventories 11,067 10,965 (b) Financial assets (i) Investments 7,408 7,492 (ii) Trade receivables 6,504 8,092 (iii) Cash and cash equivalents 1,632 1,312 (iv) Bank Balances other than (iii) above 1,416 887 (v) Others 341 291 (c) Current Tax Asset(Net) 31 (c) Other current assets 2,797 3,088 Total current assets 31,165 32,157 TOTAL ASSETS 77,310 69,323 EQUITY AND LIABILITIES (a) Equity share capital 1,762 1,759 (b) Other Equity 46,712 39,947 Equity attributable to shareholders of the Company 48,474 41,706 Non Controlling Interest 248 217 Total equity 48,722 41,923 Non-current liabilities (a) Financial liabilities (i) Borrowings 4,712 3,424 (ii) Other financial liabilities 37 50 (b) Provisions 534 509 (c) Deferred tax liabilities (Net) 1,080 882 Total Non-current liabilities 6,364 4,865 Current liabilities (a) Financial liabilities (i) Borrowings 4,403 4,497 (ii) Trade payables 13,027 13,301 (iii) Other financial liabilities 1,737 1,203 (b) Other current liabilities 1,754 2,317 (c) Provisions 919 905 (d) Current tax Liabilities (Net) 385 310 Total Current liabilities 22,225 22,535 TOTAL EQUITY AND LIABILITIES 77,310 69,323 In INR Mn 31.

Thank You For any queries and feedback please contact : investors@mail.dabur